Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEREIDA: Plitidepsin versus control in immunocompromised adults hospitalized with symptomatic COVID-19
2022-002489-34Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- Oct 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of plitidepsin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by PharmaMar. Primary endpoint: Efficacy primary endpoint. Started Oct 2022; status: terminated.
02
Drugs
plitidepsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002489-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002489-34.